Valneva SE
World Trade Center Lyon, Tour Oxygène
10-12 boulevard Marius Vivier Merle
Lyon
69003
France
Tel: 33-4-78-76-61-01
Website: http://www.valneva.com/
About Valneva SE
Valneva is a fully integrated vaccine company that specializes in the development, manufacture and commercialization of innovative vaccines with a mission to protect people from infectious diseases through preventative medicine.LEADERSHIP:
CEO: Thomas Lingelbach
CFO: Reinhard Kandera
144 articles about Valneva SE
-
The Danish company’s vaccine candidate met all co-primary endpoints in a late-stage study in adults and adolescents just months after publishing trial data for elderly patients, as it seeks to challenge Valneva.
-
Valneva Supervisory Board Recommends Transition from a Two-Tier Governance Model to a Board of Directors
6/22/2023
ValnevaSE, a specialty vaccine company, announced that its Supervisory Board has recommended a change of governance model.
-
Valneva Announces Successful Outcome of its AGM and the Appointment of Pfizer’s Former Vaccine R&D Head to its Supervisory Board
6/21/2023
ValnevaSE announced that all the resolutions recommended by the Management Board were approved by the shareholders at its Annual General Meeting held in Lyon, France.
-
Valneva’s chikungunya vaccine candidate VLA1553 showed that the shot safely and rapidly induced high rates of seroprotection. Merck earlier in 2023 discontinued its chikungunya program.
-
Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet
6/13/2023
Valneva SE, a specialty vaccine company, announces that the Company’s pivotal Phase 3 data for its single-shot chikungunya vaccine candidate, VLA1553, have been published in The Lancet, the world’s leading peer-reviewed medical journal.
-
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June 2023
5/31/2023
ValnevaSE, a specialty vaccine company, announced that its senior management will attend the Jefferies Healthcare Conference, Goldman Sachs Annual Global Healthcare Conference and the Stifel European Healthcare Conference.
-
Valneva Announces the Availability of Documentation for its Shareholder Meeting
5/31/2023
ValnevaSE, a specialty vaccine company, announced the availability of documentation for its Combined General Meeting to be held on June 21, 2023 at 2 p.m. CEST, at the hotel InterContinental Lyon – Hotel Dieu, 20 Quai Jules Courmont, 69002 Lyon.
-
Valneva Files for Chikungunya Vaccine Authorization with Health Canada
5/30/2023
ValnevaSE, a specialty vaccine company, announces the filing of a regulatory application with Health Canada for marketing approval of the Company’s single-shot chikungunya vaccine candidate, VLA1553, in persons aged 18 years and above.
-
Valneva Reports First Quarter 2023 Financial Results and Provides Corporate Updates
5/4/2023
Valneva SE reported its first quarter financial results ending March 31, 2023, and provided corporate updates.
-
Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.
3/30/2023
Valneva SE, a specialty vaccine company, announced it will present on its single-shot chikungunya vaccine candidate, VLA1553, and host a roundtable on Zika vaccines next week at the 23rd World Vaccine Congress in Washington, D.C.
-
Valneva Reports Full Year 2022 Results and Provides Corporate Updates
3/23/2023
Valneva SE a specialty vaccine company, reported its consolidated financial results for the year ending December 31, 20224 and provided corporate updates.
-
Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001
3/2/2023
Valneva SE, a specialty vaccine company, announced additional data from remaining clinical studies and an update on regulatory submissions for its inactivated COVID-19 vaccine, VLA2001.
-
Valneva to Present at the Cowen 43rd Annual Healthcare Conference
3/1/2023
ValnevaSE announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at the Cowen 43rd Annual Healthcare Conference, to take place in-person March 6 - 8, 2023 in Boston, Massachusetts.
-
Pfizer and Valneva are dropping approximately half of enrolled participants in the Phase III VALOR study for their Lyme disease vaccine candidate, VLA15.
-
Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15
2/17/2023
Pfizer Inc. and Valneva SE announce that Pfizer, as the study sponsor, has decided to discontinue a significant percentage of participants in the U.S. who had been enrolled in the Vaccine Against Lyme for Outdoor Recreationists Phase 3 clinical study.
-
Valneva Reports Full Year 2022 Revenue and Cash, Provides First 2023 Guidance
2/16/2023
Valneva SE a specialty vaccine company, reported its revenue and cash balance for the full year 2022 and provided first full year 2023 sales guidance.
-
Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate
2/14/2023
Valneva SE, a specialty vaccine company, announced that it completed enrollment and vaccination for a Phase 3 trial in adolescents, VLA1553-321, of its single-shot chikungunya vaccine candidate, VLA1553.
-
Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine
12/30/2022
ValnevaSE, a specialty vaccine company, reported further heterologous booster data from an exploratory, small clinical study for its inactivated COVID-19 vaccine, VLA2001.
-
Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum
12/21/2022
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that members of its management team including Thomas Lingelbach, CEO and Peter Bühler, CFO will hold investor meetings during the 41st Annual J.P. Morgan Healthcare Conference, January 9 – 12, 2023 in San Francisco and the Oddo BHF Forum, January 5 - 6, 2023 in Lyon France.
-
Valneva Hosts Investor Day in New York City - December 06, 2022
12/6/2022
Saint-Herblain, December06, 2022 – Valneva SE, a specialty vaccine company, is hosting an in-person investor day in New York City to discuss the Company’s current vaccine pipeline, commercial products, and future directions.